Special Report: MCG Pharma can now legally import its cannabis-based CannEpil treatment into the UK, laying the foundation for wider distribution.

 The European-focused bio-pharma company says it has received a Controlled Drug Import License Permit, meaning it can expand its distribution within the UK’s medicinal cannabis market via its partner Lenis, a European pharmaceutical company.

MGC Pharmaceuticals (ASX:MXC) also told investors this morning it had received purchase orders for CannEpil in Australia and the UK through its licensed distribution partners, with delivery scheduled for this month.

CannEpil is an orally-administered medical cannabis treatment for drug-resistant (or refractory) epilepsy, which accounts for about 30 per cent of all epilepsy cases.

Epilepsy affects around one in every 100 people in the UK, with more than 500,000 people diagnosed.

<< Learn more about MGC Pharma’s treatments

Preparing to grow

MGC also says it is progressing with negotiations with additional Australian and UK distribution partners to further expand distribution both CannEpil and CogniCann, its cannabis treatment for patients aged 65 and over with mild dementia and Alzheimer’s.

Recruitment for its Phase IIb clinical trial for CogniCann is currently underway with the University of Notre Dame in Western Australia.

MGC managing director Roby Zomer said receipt of the permit will significantly expand the potential distribution of CannEpil.

“With first purchase orders from the UK and Australian licensed distribution partners already received, and new distribution deals expected to be signed in the coming weeks, our expanded distribution in Australia, Europe and the UK will mean we will be able to provide more patients in need with access to CannEpil and our other investigational medicinal products (IMPs).”



This story was developed in collaboration with MGC Pharmaceuticals, a Stockhead advertiser at the time of publishing.
 This advice has been prepared without taking into account your objectives, financial situation or needs. You should, therefore, consider the appropriateness of the advice, in light of your own objectives, financial situation or needs, before acting on the advice. If this advice relates to the acquisition, or possible acquisition, of a particular financial product, the recipient should obtain a disclosure document, a Product Disclosure Statement or an offer document (PDS) relating to the product and consider the PDS before making any decision about whether to acquire the product.